Compass Pathways falls; fast-track review of its psychedelic treatment blocked, media reports say

COMPASS Pathways

04/02/2026 15:55

** Shares of drug developer Compass Pathways CMPS.O fall 3.6% to $6.36

** STAT News reports Trump administration officials vetoed the Food and Drug Administration's plan to fast-track the review of co's psychedelic treatment for severe depression

** The experimental therapy, COMP360, is based on the psychedelic compound, psilocybin, and is designed as a short-term, episodic alternative to daily antidepressants

** Co had previously said it is pulling forward the expected launch of its experimental psilocybin-based depression therapy by 9 to 12 months after a positive meeting with FDA

** The company did not immediately respond to a Reuters request for comment

** Reuters could not immediately verify the report

** Stock was up 82.5% in 2025

 (Reporting by Sneha S K)

 ((Sneha.SK@thomsonreuters.com))